Ameriprise Financial Inc. Sells 9,662 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Ameriprise Financial Inc. lowered its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 8.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 106,956 shares of the company's stock after selling 9,662 shares during the period. Ameriprise Financial Inc. owned about 0.23% of Omnicell worth $4,762,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Smartleaf Asset Management LLC grew its position in shares of Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after buying an additional 273 shares during the last quarter. Summit Investment Advisors Inc. grew its position in shares of Omnicell by 6.9% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company's stock valued at $213,000 after buying an additional 307 shares during the last quarter. Van ECK Associates Corp grew its position in shares of Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after buying an additional 315 shares during the last quarter. First Horizon Advisors Inc. grew its position in shares of Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after buying an additional 355 shares during the last quarter. Finally, Redmond Asset Management LLC grew its position in shares of Omnicell by 0.3% in the 4th quarter. Redmond Asset Management LLC now owns 121,209 shares of the company's stock valued at $5,396,000 after buying an additional 371 shares during the last quarter. Institutional investors own 97.70% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Piper Sandler reissued an "overweight" rating on shares of Omnicell in a research note on Friday, May 23rd. Wells Fargo & Company reissued an "overweight" rating and issued a $37.00 price objective (up from $35.00) on shares of Omnicell in a research note on Friday, May 23rd. Benchmark dropped their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Wall Street Zen raised Omnicell from a "hold" rating to a "buy" rating in a research note on Tuesday, May 20th. Finally, JPMorgan Chase & Co. dropped their price objective on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, Omnicell presently has an average rating of "Moderate Buy" and a consensus target price of $44.83.

Omnicell Stock Up 1.6%

OMCL stock traded up $0.46 during trading on Thursday, reaching $29.83. 574,267 shares of the stock were exchanged, compared to its average volume of 567,023. The firm's 50 day moving average is $30.51 and its 200 day moving average is $38.21. Omnicell, Inc. has a twelve month low of $22.66 and a twelve month high of $55.75. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.40 billion, a P/E ratio of 110.49, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. The business had revenue of $269.67 million for the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The firm's revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.03 EPS. As a group, research analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.